Editorial Article
Microbiology Is the Only Discipline in Diagnostics Where the Price of a Test Is Rising
Editorial analysis accompanying the Global Microbiology Diagnostics Market Report, 2026–2033.
Every discipline in in vitro diagnostics is being repriced downward. Clinical chemistry deflates at roughly 1.3% a year. Haematology loses about 6.4% of revenue per result across the forecast, because the complete blood count became a commodity and the value migrated to whatever gets added to it. Microbiology runs the other way: realised revenue per test rises from USD 2.777 in 2025 to USD 2.991 in 2033 — 7.7% across eight years, or 0.93% a year.
The obvious reading is pricing power. It is not. It is the one discipline where the billable unit changed, and both halves of that change sit inside the same three numbers.
Two series and the gap between them
Volume goes from 3,180 million tests to 4,410 million, a 4.17% CAGR. Revenue goes from USD 8,830 million to USD 13,190 million, a 5.14% CAGR. Revenue outgrows volume by 97 basis points a year, and that gap is the whole of the per-test rise. It decomposes cleanly:
- Constant-menu price: −1.80% a year. Hold the 2025 code mix fixed and let each code drift at its own rate, and the discipline deflates.
- Mix: +2.73% a year. The basket fills with codes that cost more than the ones they sit beside.
Both are true at once. The price of a given microbiology test is falling; the price of the average microbiology test is rising. The second happens only because the first is being offset by substitution — by selling a different and more expensive test, not by charging more for the same one.
The specimen did not change
A blood culture in 2015 was a bottle, an incubator and a result. The same specimen today is a bottle, a bottle charge, an identification — increasingly by MALDI-TOF — a susceptibility determination, and, where that determination is molecular, a separate test on a separate code. The labour is broadly unchanged. The number of chargeable events is not.
That is why the two largest classes in the discipline are also its two slowest. Blood culture systems and consumables are USD 2,120 million, growing 4.35%. Culture media, specimen collection and processing are USD 1,700 million, growing 2.62%. Together the culture block is 43.26% of the 2025 base and 28.67% of the increment to 2033. Molecular microbiology, syndromic panels, identification and automation are 25.37% of the base and 39.68% of the increment.
| Segment | 2025 (USD m) | 2033 (USD m) | CAGR |
|---|---|---|---|
| Blood culture systems and consumables | 2,120 | 2,980 | 4.35% |
| Culture media, collection and processing | 1,700 | 2,090 | 2.62% |
| Antimicrobial susceptibility testing | 1,480 | 2,290 | 5.61% |
| Molecular microbiology, organism-specific | 1,340 | 2,030 | 5.33% |
| Microbial identification (MALDI-TOF and biochemical) | 1,290 | 1,860 | 4.68% |
| Syndromic and blood-culture ID panels | 590 | 1,060 | 7.60% |
| Metagenomic and sequencing-based ID | 170 | 480 | 13.85% |
| Lab automation, imaging and middleware | 140 | 400 | 14.02% |
| Total | 8,830 | 13,190 | 5.14% |
The two fastest-growing lines in that table — metagenomic identification at 13.85% and laboratory automation at 14.02% — are 3.5% of the base between them. The money that moves the discipline is in blocks growing at four and five per cent.
The company that published the argument
bioMérieux discloses enough to see the mechanism without inferring it. Microbiology revenue was EUR 1,339 million, up 4% — 6.3% excluding China. Inside it, BIOFIRE non-respiratory panels were EUR 598 million, up 10%. SPOTFIRE was EUR 168 million, up 84%.
The culture grows at four. The panel attached to the culture grows at ten. The instrument that runs the panel grows at eighty-four. Those are three rates of change within a single discipline in a single year, and they are not describing three markets. They are describing one workflow being rebilled at progressively finer resolution.
The payment schedule has noticed
CMS’s preliminary CY 2027 Clinical Laboratory Fee Schedule cuts 224 microbiology codes by a weighted median of 19.3% — harder than clinical chemistry at 16%, softer than molecular pathology at 22%, and joint-second hardest of the six published categories. Of 1,528 priced codes, 1,171 fall: 76.6% of the schedule, so this is not a targeted correction.
Put the two findings in one sentence and the discipline’s position is clear. Microbiology’s revenue per test rises because its codes multiply, and the fee schedule is now cutting the codes. The 15%-a-year phase-in through 2029 defers that cut rather than forgiving it — roughly 6.4% a year on the affected codes, compounding against a market whose constant-menu price is already deflating at 1.8%.
What the arithmetic cannot tell you
The 3,180 million test volume series is modelled from the revenue construction. No vendor publishes a microbiology test count, and no trade body publishes one for this discipline either. The direction of the finding follows from the mix arithmetic and survives alternative assumptions about volume. The absolute level of revenue per test does not, and it is stated as a construct rather than as a measurement.
Companion analyses in this cluster
Three analyses sit alongside it. BD Is Selling the World’s Leading Blood Culture Franchise and Leaving Diagnostics examines why the largest vendor in the discipline is exiting the category’s reporting perimeter in the same cycle. Medicare Cut 224 Microbiology Codes by 19.3 Per Cent takes the fee schedule apart code by code and shows what the phase-in does to a laboratory’s budget. And The Antibiotic Pipeline Is the Ceiling Under the Microbiology Test Menu sets out the pharmacological limit on how far mix can carry the discipline.
Related research: Global Microbiology Diagnostics Market, 2026–2033; Global In Vitro Diagnostics Market; Global IVD Reagents and Consumables Market, where the same mix-versus-price split is measured across the reagent layer; and Global Clinical Chemistry and Urinalysis Market, the discipline on the other side of the comparison.
About the method
70% secondary, 30% primary. Revenue, volume, price and mix are built from disclosed vendor revenue — bioMérieux’s FY2025 segment and application reporting, BD’s FY2025 results and Bruker’s 2025 accounts — reconciled against a stated residual rather than against published aggregates. The fee-schedule detail is read from the issuing body. No market-research competitor material is cited, quoted or used to set any level.
The primary layer is 41 depth interviews across 12 markets, 26 open-ended tender-cycle interviews, a 158-respondent laboratory survey and structured observation at four conferences. It establishes mechanism and sequence, carries no figure, and the counts are stated so they can be reconciled against programme records.
Sources
- bioMérieux — FY2025 consolidated financial statements (microbiology EUR 1,339m; BIOFIRE non-respiratory EUR 598m; SPOTFIRE EUR 168m)
- BD — FY2025 fourth quarter and full year results (Diagnostic Solutions revenue and instrument utilisation commentary)
- Bruker — FY2025 results and 2025 Annual Report (MALDI-TOF microbiology revenue)
- CMS — preliminary CY 2027 Clinical Laboratory Fee Schedule fact sheet (224 microbiology codes; 1,528 priced codes; 15% annual phase-in to 2029)
- CLSI M47 and EUCAST susceptibility-testing standards (panel composition and reporting conventions)
- WHO Global Tuberculosis Report 2025 (culture and molecular case-finding volumes)
- GBD 2021 Antimicrobial Resistance Collaborators, The Lancet (2024) — burden of bacterial resistance, used for scale only
- Regulation (EU) 2017/746 on in vitro diagnostic medical devices (Class D transition schedule)
Company and entity links
Frequently Asked Questions
Why is the price per microbiology test rising when every individual code is falling?
Because the billable unit changed. Holding the 2025 code mix fixed, microbiology prices deflate about 1.8% a year. But the basket fills with more expensive codes — an identification, a susceptibility panel, a molecular determination that used to be part of the culture result. That mix effect adds about 2.73% a year, so realised revenue per test rises even though nothing got more expensive.
What is the difference between constant-menu price and mix?
Constant-menu price lets each code drift at its own rate while holding the mix of codes fixed at the 2025 basket. Mix measures the effect of the basket itself changing — more codes per specimen, and more expensive codes taking share. Revenue per test is the product of the two, which is why the discipline can deflate at 1.8% and inflate at 0.93% in the same eight years.
How reliable is the microbiology test volume figure?
It is modelled from the revenue construction, not disclosed by any vendor — nobody publishes a microbiology test count. The direction of the per-test finding follows from the mix arithmetic and is robust. The absolute level of revenue per test, USD 2.777 to USD 2.991, is a construct and should be read as one.
Is the CMS fee schedule cut already in force?
No. The 19.3% weighted median across 224 microbiology codes comes from the preliminary CY 2027 Clinical Laboratory Fee Schedule, and the weighted medians can move before the final rule. The phase-in is 15% a year through 2029, which defers the cut rather than forgiving it.